Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1678

Shown on this page

Current sort

Live official records

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Colorectal Cancer, Rectal Cancer
Interventions: Botensilimab, Balstilimab, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Endometrial Cancer, Cervical Cancer
Interventions: Ivonescimab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 531
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions: Plant based meals; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Sarcoma, Merkel Cell Carcinoma
Interventions: CRD3874; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
Interventions: Motixafortide, Cemiplimab, Gemcitabine, Nab paclitaxel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more

Conditions: Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: rituximab, prednisone, Geriatric Assessment; Drug · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Cancer
Interventions: Blood sample collection; Other
Lead sponsor: Harbinger Health; Industry
Eligibility: 45 Years and older
Enrollment: 2,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 42
States / cities: Coronado, California • Poway, California • San Diego, California + 38 more

Conditions: Cancer Patients
Interventions: The Integrated Cancer Care Access Network (ICCAN), Usual and Customary Group (U&C); Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 11
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Triple Negative Breast Cancer
Interventions: BL-B01D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 22
States / cities: Beverly Hills, California • Duarte, California • Orange, California + 17 more

Conditions: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Interventions: cabozantinib, nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Memorial Sloan Kettering Cancer Center

Filter and sort this campus

Live official records

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

A Study of CRD3874-SI in People With Solid Tumors

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

Prospective Study to Assess a Diagnostic Aid for Cancer

Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

About this Memorial Sloan Kettering Cancer Center institution page